NCT00516841

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Facet Biotech · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.

Conditions

• Ovarian Cancer
• Peritoneal Neoplasms

Interventions

Type	Name	Description
DRUG	Volociximab	15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops

Timeline

• Start date: 2007-08-01
• Primary completion: 2008-04-01
• Completion: 2008-04-01
• First posted: 2007-08-16
• Last updated: 2012-08-23

Locations

23 sites across 2 countries: United States, Canada